202409-31-2

Usage

Uses

Used in Pharmaceutical Research and Development:
Etoricoxib Impurity 11 is used as a reference standard for ensuring the safety and efficacy of etoricoxib-based medications. It is crucial in the quality control process, helping to maintain the consistency and reliability of etoricoxib drug products in the market.
Used in Quality Control Processes:
Etoricoxib Impurity 11 is utilized for characterizing and quantifying impurities in etoricoxib drug products, which is essential for regulatory compliance and ensuring the overall quality of the medication.
Used in Regulatory Compliance:
The presence and quantification of Etoricoxib Impurity 11 in etoricoxib drug products are critical for meeting regulatory requirements, ensuring that the medications are safe and effective for patients.

Upstream product

• 202409-86-7 2,5-dichloro-3-[4-(methylsulfonyl)phenyl]pyridine 
• 74-88-4 methyl iodide 
• 1349546-82-2 C₁₆H₁₂ClN₃O₂S 
• 202409-85-6 5-chloro-3-(4-(methylsulfonyl)phenyl)pyridin-2-ol 
• 4214-79-3 5-chloro-2-pyridinol 
• 202409-81-2 2-bromo-5-chloro-3-(4-(methylsulfonyl)phenyl)pyridine 
• 329214-79-1 3-(4,4,5,5,-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridine 
• 1692-25-7 3-pyridylboronic acid 
• 40061-50-5 2-(4-methanesulfonyl-phenyl)-1-pyridin-3-yl-ethanone 
• 99414-75-2 2,3-dichloroacrolein 
• 26910-68-9 2,3-dichloropropenal 
• 50704-42-2 2-chloromalonaldehyde 
• 202409-80-1 5-chloro-3-(4-methylsulfonylphenyl)-2-pyridinamine 
• 217090-19-2 5-chloro-3-(4-methylthiophenyl)-2-pyridinamine 

Relevant academic research and scientific papers

NHC-Catalyzed Deamination of Primary Sulfonamides: A Platform for Late-Stage Functionalization

Herein we describe the development and application of a method for the mild, late-stage conversion of primary sulfonamides to several other other functional groups. These reactions occur via initial reductive deamination of sulfonamides to sulfinates via an NHC-catalyzed reaction of transiently formed N-sulfonylimines. The method described here is tolerant of nearly all common functional groups, as exemplified by the late-stage derivatization of several complex pharmaceutical compounds. On the basis of the prevalence of sulfonamide-containing drugs and building blocks, we have developed a method to enable sulfonamides to be applied as versatile synthetic handles for synthetic chemsitry.

Preparation technology of etoricoxib and reference substance 5-chloro-3-(4-(methyl sulphonyl)phenyl)-2,3-bipyridine of etoricoxib

The invention discloses a preparation technology of etoricoxib and a reference substance 5-chloro-3-(4-(methyl sulphonyl)phenyl)-2,3-bipyridine of etoricoxib. The preparation technology comprises steps as follows: 5-chloro-2-hydroxypyridine is taken as a raw material and subjected to a substitution reaction, and 5-chloro-3-iodopyridine-2-ol is obtained; 5-chloro-3-iodopyridine-2-ol is subjected to a coupled reaction, and 5-chloro-3-(4-(methyl sulphonyl)phenyl)pyridine-2-ol is obtained; 5-chloro-3-(4-(methyl sulphonyl)phenyl)pyridine-2-ol is subjected to the substitution reaction, and 2-bromo-5-chloro-3-(4-(methyl sulphonyl)phenyl)pyridine is obtained; 2-bromo-5-chloro-3-(4-(methyl sulphonyl)phenyl)pyridine is subjected to the coupled reaction, a target product etoricoxib or the reference substance 5-chloro-3-(4-(methyl sulphonyl)phenyl)-2,3-bipyridine of etoricoxib is obtained, and the total yield can reach 18%. The route is one novel technology for synthesizing etoricoxib or the reference substance 5-chloro-3-(4-(methyl sulphonyl)phenyl)-2,3-bipyridine of etoricoxib, and the blank of a synthesis method of the reference substance 5-chloro-3-(4-(methyl sulphonyl)phenyl)-2,3-bipyridine of etoricoxib in China is filled up accordingly.

PROCESS FOR MAKING 2-ARYL-3-ARYL-5-HALO PYRIDINES USEFUL AS COX-2 INHIBITORS

The invention encompasses a process for making compounds of Formula (I) useful in the treatment of cyclooxygenase-2 mediated diseases.

Method of treating cancer

The present invention relates to methods of treating cancer using a combination of a compound which is a PSA conjugate and an NSAID compound, which methods comprise administering to said mammal, either sequentially in any order or simultaneously, amounts of at least two therapeutic agents selected from a group consisting of a compound which is a PSA conjugate and an NSAID compound. The invention also relates to methods of preparing such compositions.

Process for making diaryl pyridines useful as cox-2 inhibitors

The invention encompasses a process for making compounds of Formula I useful in the treatment of cyclooxygenase-2 mediated diseases.

Substituted pyridines as selective cyclooxygenase-2 inhibitors

The invention encompasses the novel compound of Formula I as well as a method of treating COX-2 mediated diseases comprising administration to a patient in need of such treatment of a non-toxic therapeutically effective amount of a compound of Formula I. STR1 The invention also encompasses certain pharmaceutical compositions for treatment of COX-2 mediated diseases comprising compounds of Formula I.

2-pyridinyl-3(4-methylsulfonyl)phenylpyridines: Selective and orally active cyclooxygenase-2 inhibitors

A series of novel 2-pyridinyl-3-(4-methylsulfonyl)phenylpyridines has been synthesized and evaluated with respect to their ability to inhibit the isozymes of cyclooxygenase, COX-1, and COX-2. Optimum COX-2 activity is observed by introduction of a substituent at C5 of the central pyridine. 5- Chloro-3-(4-methylsulfonyl)phenyl-2(2-methyl-5-pyridinyl)pyridine 33 was identified as the optimum compound in this series.